Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT06485687

Low Intensity Focused Ultrasound for Binge Eating Disorder

This study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of LIFU for neuromodulation in patients with Binge Eating Disorder (BED)

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

22 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

West Virginia University: Rockefeller Neuroscience Institute

Morgantown, West Virginia, 26506, United States

About this study

The primary objective is to evaluate the safety, feasibility and tolerability of LIFU as an adjunct neuromodulatory treatment for BED

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Males and non-pregnant females, 22 - 65 years of age.
  • Participant meets DSM-5 criteria for moderate to extreme BED.
  • Weight ≤450lb to accommodate in MRI.
  • Shoulder width of ≤65 inches to accommodate in MRI.
  • The neuromodulation targets are visible on MRI for target selection.
  • Participant is able and willing to give informed consent.

Exclusion criteria

  • Unable to undergo MR-imaging because of implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent make-up or small metal fragments in the eye that welders and other metal workers may have, or if candidates are uncomfortable in small spaces (have claustrophobia).
  • Participants with more than 30% of the skull area traversed by the sonication pathway are covered by scars, scalp disorders (e.g., eczema), atrophy of the scalp, or implanted objects in the skull or the brain.
  • Participants with known untreated or unstable cardiac status or hypertension
  • Evidence of substance (alcohol or other drug) use disorder during the previous 12 months (assessed via SCID-5).
  • Past or present diagnosis of schizophrenia, psychotic disorder or bipolar disorder (assessed via SCID-5)
  • Participant who is currently participating in another clinical investigation with an active treatment arm.
  • Use of any medications that, in the opinion of the Investigator, may put the participant at higher risk for AEs, or impair the participant's ability to perform complete study procedures.
  • Participant is considered to be a poor surgical or study candidate, which may include, but is not limited to the following: any medical, social, or psychological problem that could complicate the required procedures and evaluations of the study in the judgment of the investigator.
  • Participant is pregnant/lactating or planning to be pregnant.

Treatment and study plan

LIFU Neuromodulation

Device

Subjects will undergo a single LIFU of the target brain region

Primary outcomes

  1. Occurrence of Treatment Emergent Adverse Events

    Time frame: [baseline and day 7 and 90 after study procedure

    All adverse events that are related to LIFU procedure will be assessed

Secondary outcomes

  1. Effect of LIFU on Food craving

    Time frame: Day 1, Day 7, Day 30, Day 60, Day 90; comparisons will be made relative to baseline, pre-LIFU.

    Visual Analog scale and food diary

Sponsors and collaborators

Lead sponsor

Ali Rezai

Other

Registry information

Official study title

Early Feasibility Study of Low-Intensity Focused Ultrasound (LIFU) Neuromodulation in Patients With Binge Eating Disorder (BED)

Important dates

Study start
2024
Primary completion
2026
Study completion
2027
First posted
Jul 3, 2024
Registry last updated
Dec 18, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.